Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

Abstract Background The ORBE II study aimed to describe the characteristics and clinical outcomes of adult patients with severe eosinophilic asthma (SEA) treated with benralizumab in a real-world setting in Spain. Methods ORBE II (NCT04648839) was an observational, retrospective cohort study in adul...

Full description

Bibliographic Details
Main Authors: Alicia Padilla-Galo, Isabel Moya Carmona, Pilar Ausín, Luis Carazo Fernández, Ismael García-Moguel, José Luis Velasco-Garrido, Rubén Andújar-Espinosa, Francisco Casas-Maldonado, Eva Martínez-Moragón, Carlos Martínez Rivera, Elisabet Vera Solsona, Fernando Sánchez-Toril López, Andrea Trisán Alonso, Marina Blanco Aparicio, Marcela Valverde-Monge, Borja Valencia Azcona, Marta Palop Cervera, Javier Nuevo, Jesús Sánchez Tena, Gustavo Resler, Elisa Luzón, Alberto Levy Naon
Format: Article
Language:English
Published: BMC 2023-09-01
Series:Respiratory Research
Subjects:
Benralizumab
Severe eosinophilic asthma
ORBE II
Real world evidence
Biologics
Chronic rhinosinusitis with nasal polyps
Online Access:https://doi.org/10.1186/s12931-023-02539-7

Internet

https://doi.org/10.1186/s12931-023-02539-7

Similar Items